• Nonivamide: Capsaicin Analog for Advanced TRPV1 Cancer Model

  2026-05-09

  Nonivamide, a next-generation capsaicin analog, empowers researchers with precise control over TRPV1-driven apoptosis and cancer cell growth inhibition. Its robust solubility profile and validated efficacy in both in vitro and in vivo oncology models set it apart as a cornerstone tool for translational cancer and neuroimmune research.

• Tofacitinib Citrate (CP-690550 Citrate) in Immune Regulation

  2026-05-08

  Tofacitinib citrate (CP-690550 citrate) empowers immune regulation and inflammatory disorder research through highly selective JAK3 inhibition. This guide details advanced experimental workflows, protocol enhancements, and troubleshooting strategies, leveraging new insights into vascular and cytokine-driven endothelial responses.

• Intestinal TM6SF2 Safeguards Against MASH via the Gut–Liver

  2026-05-08

  This study uncovers the protective role of intestinal TM6SF2 against metabolic dysfunction-associated steatohepatitis (MASH) by regulating gut barrier function and microbiota composition. The findings reveal a mechanistic link between gut-derived lipid signaling and hepatic inflammation, suggesting new intervention strategies.

• Anlotinib Hydrochloride: Multi-Target TKI for Angiogenesis A

  2026-05-07

  Anlotinib hydrochloride enables precise, highly potent inhibition of tumor angiogenesis by targeting VEGFR2, PDGFRβ, and FGFR1. Its superior activity streamlines endothelial migration and tube formation assays, providing cancer researchers a robust, reproducible platform for anti-angiogenic drug discovery.

• Revisiting Sumatriptan Metabolism: CYP and MAO Pathway Insig

  2026-05-07

  This study challenges the prevailing view that sumatriptan is metabolized exclusively by MAO A, presenting evidence that cytochrome P450 enzymes (CYP1A2, CYP2C19, CYP2D6) also play a significant role. These findings refine our understanding of drug metabolism pathways and have implications for neuropharmacology and drug interaction studies.

• Metronidazole in Research: OAT3 Inhibition & Microbiome Modu

  2026-05-06

  Metronidazole offers researchers a dual-action tool, uniquely bridging antimicrobial activity and selective inhibition of organic anion transporters. This article provides stepwise experimental guidance, troubleshooting insights, and protocol precision for leveraging Metronidazole in both microbiota-immunity and drug-drug interaction studies.

• Tivozanib (AV-951): Precision VEGFR Inhibition in In Vitro O

  2026-05-06

  Explore how Tivozanib (AV-951), a potent tyrosine kinase inhibitor, is redefining in vitro oncology research through selective VEGFR pathway targeting. This article delivers unique technical insights, protocol guidance, and evidence-based analysis of Tivozanib’s role in anti-angiogenic therapy.

• QPRT Drives Breast Cancer Invasion via Purinergic Signaling

  2026-05-05

  Liu et al. (2021) reveal that quinolinate phosphoribosyltransferase (QPRT) enhances breast cancer cell invasiveness by promoting myosin light chain phosphorylation, implicating a purinergic signaling axis. This mechanistic insight identifies QPRT and its downstream pathways, such as P2Y11 receptor signaling, as potential targets for therapeutic intervention and advanced cancer biology research.

• Human Gastrin I Peptide: Optimizing GI Organoid Pathway Rese

  2026-05-05

  Human Gastrin I peptide enables precise modulation of gastric acid secretion pathways in advanced organoid and cell-based models. This article details experimental workflows, troubleshooting insights, and protocol refinements that maximize data reliability in gastrointestinal physiology studies.

• Metronidazole: OAT3 Inhibition and Microbiota Modulation in

  2026-05-04

  Metronidazole (2-(2-methyl-5-nitroimidazol-1-yl)ethanol) uniquely bridges antibiotic activity and organic anion transporter (OAT3) inhibition, enabling integrated workflows in microbiota-immune and drug interaction studies. This article delivers advanced, protocol-focused guidance for maximizing the compound’s dual utility in experimental research.

• Metronidazole: OAT3 Inhibition and Translational DDI Modelin

  2026-05-04

  Explore Metronidazole's dual role as an OAT3 inhibitor and nitroimidazole antibiotic. This article uniquely bridges transporter pharmacology with translational drug-drug interaction (DDI) modeling, offering advanced insights for research professionals.

• Vacuolin-1 in Lysosomal Exocytosis: Advanced Pathway Dissect

  2026-05-03

  Explore how Vacuolin-1, a potent lysosomal exocytosis inhibitor, enables nuanced investigation of Ca2+-dependent membrane dynamics and disease signaling. This article delivers a unique focus on mechanistic insight, assay design, and translational relevance—offering a depth not found in existing content.

• QPRT Drives Breast Cancer Invasion via Purinergic Signaling

  2026-05-02

  Liu et al. (2021) establish quinolinate phosphoribosyltransferase (QPRT) as a key promoter of breast cancer invasiveness through myosin light chain phosphorylation, implicating NAD+ metabolism and purinergic signaling. Their work demonstrates that pharmacological inhibition—using both a QPRT inhibitor and a selective P2Y11 antagonist—can reverse the invasive phenotype, providing new mechanistic insight and experimental directions for targeting metastatic progression.

• NF 340: Advancing P2Y11 Antagonist Research in Cancer Signal

  2026-05-01

  Explore how NF 340, a potent P2Y11 antagonist, is reshaping breast cancer and immunology research by enabling precise GPCR signaling modulation. This article uniquely details translational insights from recent mechanistic studies and offers advanced assay strategies.

• HDAC Inhibition Reverses EBV-Driven Plasticity in NPC Models

  2026-05-01

  This study reveals how EBV latent protein LMP1 drives dedifferentiation and stem-like plasticity in nasopharyngeal carcinoma (NPC) by repressing CEBPA through STAT5A-mediated HDAC1/2 recruitment. Importantly, HDAC inhibition restores differentiation, highlighting a promising epigenetic approach to target solid tumor plasticity and resistance.

14952 records 1/997 page Next 12345 下5页 Last page